Loading
San Diego maker of blood cancer gene tests, including the FDA companion diagnostic for FLT3 inhibitors in acute myeloid leukaemia.
Invivoscribe, based in San Diego with offices in France and China and LabPMM clinical laboratories in the US, Germany and Japan, makes the LeukoStrat CDx FLT3 Mutation Assay, the FDA companion diagnostic for midostaurin, gilteritinib and quizartinib in acute myeloid leukaemia. Its other products are clonality and measurable residual disease tests for leukaemia and lymphoma.
The FDA-approved test that decides whether a person with acute myeloid leukaemia has a FLT3 mutation and so can be offered a FLT3 inhibitor.
Shares LeukoStrat CDx FLT3 Mutation Assay, Acute myeloid leukaemia.
Shares LeukoStrat CDx FLT3 Mutation Assay, Acute myeloid leukaemia.
Shares LeukoStrat CDx FLT3 Mutation Assay, Acute myeloid leukaemia.
Shares LeukoStrat CDx FLT3 Mutation Assay, Acute myeloid leukaemia.
Shares LeukoStrat CDx FLT3 Mutation Assay, Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/